The immune profile of BRAF-MT CRC can be evaluated in future clinical trials or in the prospective cohort to enhance the understating of the tumor biology of BRAF-MT tumors and find a new treatment strategy for BRAF-MT CRC. This evidence concerns the gene BRAF and neoplasm.